Document is current
Any future updates will be listed below
-
Authors
Njomen, Evert https://orcid.org/0000-0002-3508-2638
Hayward, Rachel E. https://orcid.org/0000-0002-1080-8244
DeMeester, Kristen E.
Ogasawara, Daisuke https://orcid.org/0000-0002-2178-4698
Dix, Melissa M.
Nguyen, Tracey
Ashby, Paige
Simon, Gabriel M.
Schreiber, Stuart L.
Melillo, Bruno https://orcid.org/0000-0002-9708-5287
Cravatt, Benjamin F. https://orcid.org/0000-0001-5330-3492
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI142784)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA231991, OT2 CA278692)
Cancer Research UK (CGCATF-2021/100021)
Howard Hughes Medical Institute (GT15176)
- License Information
-
More Information
Article History
Received: 5 June 2023
Accepted: 12 July 2024
First Online: 13 August 2024
Competing interests
: G.M.S., T.N. and P.A. are employees of Vividion Therapeutics, and B.F.C. is a founder and member of the Board of Directors of Vividion Therapeutics. The other authors declare no competing interests.
